Pelacarsen - Novartis
Alternative Names: AKCEA-APO(a)-LRx; IONIS-681257; IONIS-APO(a)-LRx; IONIS-APO-LRx; ISIS-681257; ISIS-APO(a)-LRx; ISIS-APOALRx; Pelacarsen sodium; TQJ 230Latest Information Update: 22 Aug 2024
At a glance
- Originator Ionis Pharmaceuticals
- Developer Novartis
- Class Antihyperlipidaemics; Antisense oligonucleotides
- Mechanism of Action Apolipoproteins A expression inhibitors; Gene silencing
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Hyperlipoproteinaemia
Most Recent Events
- 24 Apr 2024 Novartis Pharmaceuticals initiates a phase III trial for Hyperlipoproteinaemia in USA (SC) in May 2024 (NCT06267560)
- 07 Mar 2024 Novartis initiates a phase II trial in Hyperlipoproteinaemia in United Kingdom, Israel, USA, Canada, Czech Republic, Switzerland (SC) (NCT05646381)
- 20 Feb 2024 Novartis Pharmaceuticals plans a phase III trial in Hyperlipoproteinaemia in USA (SC) in May 2024 (NCT06267560)